Publications

Export 13 results:
Author Title Type [ Year(Asc)]
Filters: Author is Parikh, Sagar V  [Clear All Filters]
2021
Popescu C, Golden G, Benrimoh D, Tanguay-Sela M, Slowey D, Lundrigan E, Williams J, Desormeau B, Kardani D, Perez T et al..  2021.  Evaluating the Clinical Feasibility of an Artificial Intelligence-Powered, Web-Based Clinical Decision Support System for the Treatment of Depression in Adults: Longitudinal Feasibility Study.. JMIR Form Res. 5(10):e31862.
Tanguay-Sela M, Benrimoh D, Popescu C, Perez T, Rollins C, Snook E, Lundrigan E, Armstrong C, Perlman K, Fratila R et al..  2021.  Evaluating the perceived utility of an artificial intelligence-powered clinical decision support system for depression treatment using a simulation center.. Psychiatry Res. 308:114336.
Suh JSu, Fiori LM, Ali M, Harkness KL, Ramonas M, Minuzzi L, Hassel S, Strother SC, Zamyadi M, Arnott SR et al..  2021.  Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report.. Psychoneuroendocrinology. 132:105348.
Fiori LM, Orri M, Aouabed Z, Théroux JFrançois, Lin R, Nagy C, Frey BN, Lam RW, Macqueen GM, Milev R et al..  2021.  Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response.. Transl Psychiatry. 11(1):439.
Benrimoh D, Tanguay-Sela M, Perlman K, Israel S, Mehltretter J, Armstrong C, Fratila R, Parikh SV, Karp JF, Heller K et al..  2021.  Using a simulation centre to evaluate preliminary acceptability and impact of an artificial intelligence-powered clinical decision support system for depression treatment on the physician-patient interaction.. BJPsych Open. 7(1):e22.
2020
Uher R, Frey BN, Quilty LC, Rotzinger S, Blier P, Foster JA, Müller DJ, Ravindran AV, Soares CN, Turecki G et al..  2020.  Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.. J Clin Psychiatry. 81(4)
2019
Ju C, Fiori LM, Belzeaux R, Théroux J-F, Chen GGang, Aouabed Z, Blier P, Farzan F, Frey BN, Giacobbe P et al..  2019.  Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants.. Transl Psychiatry. 9(1):254.
Belzeaux R, Fiori LM, Lopez JPablo, Boucekine M, Boyer L, Blier P, Farzan F, Frey BN, Giacobbe P, Lam RW et al..  2019.  Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment.. J Clin Psychiatry. 80(3)
2017
Baskaran A, Farzan F, Milev R, Brenner CA, Alturi S, McAndrews MPat, Blier P, Evans K, Foster JA, Frey BN et al..  2017.  The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.. J Affect Disord. 227:542-549.
Lopez JPablo, Fiori LM, Cruceanu C, Lin R, Labonte B, Cates HM, Heller EA, Vialou V, Ku SM, Gerald C et al..  2017.  MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes.. Nat Commun. 8:15497.
2016
Kennedy SH, Lam RW, McIntyre RS, S Tourjman V, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, Macqueen GM et al..  2016.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.. Can J Psychiatry. 61(9):540-60.
Lam RW, Milev R, Rotzinger S, Andreazza AC, Blier P, Brenner C, Daskalakis ZJ, Dharsee M, Downar J, Evans KR et al..  2016.  Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.. BMC Psychiatry. 16:105.
2015
Parikh SV, Hawke LD, Velyvis V, Zaretsky A, Beaulieu S, Patelis-Siotis I, MacQueen G, L Young T, Yatham LN, Cervantes P.  2015.  Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder.. Bipolar Disord. 17(1):86-96.